
About DiaCarta
DiaCarta is a Healthcare company based in Richmond (United States) founded in 2011. In vitro diagnostic tests for precision medicine are provided. DiaCarta has raised $53 million across 3 funding rounds from investors including HHS, Fortune Fountain Capital and BioVeda China Fund. DiaCarta offers products and services including RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is DiaCarta, Inc. Its competitors include Guardant Health, Natera and Denali Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
DiaCarta was founded in 2011 and is based in Richmond, United States. In vitro diagnostic tests for precision medicine are developed within the biotechnology sector. The proprietary QClamp platform is employed, featuring a sequence-specific xeno-nucleic acid clamp that suppresses wild-type DNA. This enables detection of oncogenic tumor drivers and therapy resistance. Additional technologies include SuperbDNA for cervical cancer testing and multiplex barcoding for DigiPlex genotyping assays.
- Headquarters Richmond, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website diacarta.com
- Social LinkedIn X Facebook
- Legal Name Diacarta, Inc.
- Total Equity Funding$53M (USD)
in 3 rounds
- Latest Funding Round$45M (USD), Series B
Feb 2018
- InvestorsHHS
& 2 more
Products & Services of DiaCarta
DiaCarta offers a comprehensive portfolio of products and services, including RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test.
Monitors cancer treatment response through circulating DNA analysis.
Detects colorectal cancer via DNA-based screening methods.
Identifies bladder cancer markers for early diagnosis.
Detects COVID-19 virus through PCR-based methods.
Funding Insights of DiaCarta
DiaCarta has successfully raised a total of $53M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $45 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53M
- Total Rounds 3
- Last Round Series B β $45M
- First Round $594,739
(Mar 2012)
- Investors Count 3
All 3 funding rounds of DiaCarta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2018 | $45M | Series B | β | Fortune Fountain Capital | β |
| Jan 2015 | $8M | Series A | β | BioVeda China Fund | β |
| Mar 2012 | $594,739 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in DiaCarta
DiaCarta has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Fortune Fountain Capital and BioVeda China Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| fortunefountaincapital.com | ||||
VC firm funding companies in China and the US | bvcf.com | Huangpu, China | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for DiaCarta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DiaCarta
30 people are tracked at DiaCarta (15 in leadership, 6 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Dennis Gao | VP of Finance & Principle Financial Officer | Leadership |
Zheng Li | VP, Clinical Affairs | Leadership |
King Lee | VP, Regulatory | Leadership |
Michael Sha | CTO & SVP, R&D | Leadership |
Effie Ho | General Manager, Asia Pacific | Leadership |
Anne K. Vallerga | VP, External Affairs | Leadership |
Aiguo Zhang | Founder, President & CEO | Leadership |
Mauro Scimia | Senior Director Of Business Development And Clinical, Europe | Leadership |
Wei Liu | Vice President, Product Management And Marketing | Leadership |
Yuzhen Shi | Director HR | Leadership |
Michael Powell | Chief Scientific Officer | Leadership |
Anne Vallerga | Vice President Of External Affairs | Leadership |
Rachel L Chuang | R&d Director | Leadership |
C. Mark Lu | CLIA Lab Director | Leadership |
Giselle A. | Director Of Business Development | Leadership |
Dean Tsao | Medical & Scientific Advisor | Board & advisors |
Walter Bodmer | Medical & Scientific Advisor | Board & advisors |
Anthony M. Magliocco | Chair | Board & advisors |
Mickey Urdea | Medical & Scientific Advisor | Board & advisors |
Frank McCormick | Medical & Scientific Advisor | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for DiaCarta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DiaCarta
3 dated milestones of DiaCarta across 7 years, from founding to its latest funding, stage changes and deals.
- Founded DiaCarta is founded.
- Funding First funding round of $595K.
- Funding Latest funding round, Series B, of $45.0M.
Competitors of DiaCarta
DiaCarta has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Denali Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. |
Detailed competitors of DiaCarta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DiaCarta
The website of DiaCarta (diacarta.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▼ 4.8% vs previous month
Websites whose visitors overlap most with DiaCarta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| majorbio.com | 100% | 53.3K | #388,474 | View details | |
| origene.com | 93% | 122.1K | #329,769 | View details | |
| isogen-lifescience.com | 90% | View details | |||
| panomics.com | 90% | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as DiaCarta (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Diacarta
Complete news archive for DiaCarta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DiaCarta
DiaCarta was founded in 2011 and raised its 1st funding round 1 year after it was founded.
DiaCarta is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.
DiaCarta is a funded company, having raised a total of $53M across 3 funding rounds to date. The company's 1st funding round was a Grant of $594.74K, raised on Mar 2012.
DiaCarta was founded in 2011 and is based in Richmond, United States. In vitro diagnostic tests for precision medicine are developed within the biotechnology sector. The proprietary QClamp platform is employed, featuring a sequence-specific xeno-nucleic acid clamp that suppresses wild-type DNA. This enables detection of oncogenic tumor drivers and therapy resistance. Additional technologies include SuperbDNA for cervical cancer testing and multiplex barcoding for DigiPlex genotyping assays.
DiaCarta's top competitors include Guardant Health, Natera and Denali Therapeutics.
DiaCarta offers RadTox cfDNA Test, ColoScape Test, Oncuria Bladder Cancer Test, and QuantiVirus SARS-CoV-2 Test.
DiaCarta has 3 investors. Key investors include HHS, Fortune Fountain Capital, and BioVeda China Fund.
DiaCarta operates through Diacarta, Inc..
